Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; colloidal anhydrous silica; crospovidone; maize starch; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - leflunomide generichealth is indicated for the treatment of: - active rheumatoid arthritis; - active psoriatic arthritis. leflunomide generichealth is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.,the combined use of leflunomide generichealth with other disease modifying anti-rheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - leflunomide generichealth is indicated for the treatment of: - active rheumatoid arthritis; - active psoriatic arthritis. leflunomide generichealth is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.,the combined use of leflunomide generichealth with other disease modifying anti-rheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; colloidal anhydrous silica; crospovidone; maize starch; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; colloidal anhydrous silica; crospovidone; maize starch; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - leflunomide, quantity: 20 mg - tablet, uncoated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; lactose - leflunomide apotex is indicated for the treatment of: active rheumatoid arthritis; active psoriatic arthritis. genrx leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of genrx leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).